Blackstone Inc
SYRE icon

Blackstone Inc’s Spyre Therapeutics SYRE Stock Holding History

Blackstone Inc’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
120,177
-172,670
-59% -$12.6M 0.03% 97
2026
Q1 		$14.8M Sell
292,847
-208,151
-42% -$7.85M 0.06% 72
2025
Q4 		$16.4M Hold
500,998
– – 0.06% 83
2025
Q3 		$8.4M Buy
500,998
+11,750
+2% +$192K 0.03% 100
2025
Q2 		$7.32M Hold
489,248
– – 0.03% 95
2025
Q1 		$7.89M Buy
489,248
+40,047
+9% +$833K 0.03% 85
2024
Q4 		$10.5M Buy
449,201
+156,206
+53% +$4.58M 0.05% 73
2024
Q3 		$8.62M Hold
292,995
– – 0.04% 79
2024
Q2 		$6.89M Buy
292,995
+273,004
+1,366% +$9.21M 0.03% 89
2024
Q1 		$758K Hold
19,991
– – ﹤0.01% 147
2023
Q4 		$430K Buy
+19,991
New +$275K ﹤0.01% 140

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Blackstone Inc's SYRE Position: Q2 2026 in Review

Blackstone Inc reduced its Spyre Therapeutics (SYRE) stake by 59% in Q2 2026, selling an estimated $12.6M and leaving 120,177 shares worth $10.7M. The position accounts for 0.03% of the portfolio, ranked #97.

Blackstone Inc first reported a position in SYRE in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.4M in Q4 2025. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Blackstone Inc held 120,177 shares of Spyre Therapeutics worth $10.7M as of Q2 2026.
  • Blackstone Inc sold 172,670 Spyre Therapeutics shares in Q2 2026, an estimated $12.6M.
  • Spyre Therapeutics made up 0.03% of Blackstone Inc's portfolio in Q2 2026, its #97 holding.
  • Blackstone Inc first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Blackstone Inc's Spyre Therapeutics position peaked at $16.4M in Q4 2025.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.